<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677673</url>
  </required_header>
  <id_info>
    <org_study_id>Dragon Senile</org_study_id>
    <nct_id>NCT04677673</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients</brief_title>
  <acronym>RJGC-Senile</acronym>
  <official_title>Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIRENDRA KUMAR SAH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the feasibility and efficacy of neoadjuvant&#xD;
      chemotherapy (modified SOX) for elderly patients with locally advanced gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DRAGON SENILE research, Neoadjuvant Chemotherapy plus Surgery versus surgery first for&#xD;
      elderly Gastric Cancer patients, is an investigator-initiated; phase II/III, open-label,&#xD;
      randomized controlled study. The main purpose of this study is to compare the feasibility and&#xD;
      efficacy of neoadjuvant chemotherapy (modified SOX) for elderly patients with locally&#xD;
      advanced gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Five years</time_frame>
    <description>Time from randomization to death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completion rate of planned NAC</measure>
    <time_frame>Three months</time_frame>
    <description>Completion rate of planned chemotherapy before surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Grade 3/4 hematological adverse events</measure>
    <time_frame>Three months</time_frame>
    <description>Percentage of Grade 3/4 hematological adverse events during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response</measure>
    <time_frame>Four months</time_frame>
    <description>Total percentage of patients with pathological complete tumor regression (TRG1a) and sub-total tumor regression (TRG1b) in the primary tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>Two years</time_frame>
    <description>Time from randomization to relapse of the disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Elderly Patients</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>NAC PLUS SURGERY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive three cycles of the modified dose of TGO plus oxaliplatin before curative gastrectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SURGERY FIRST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo curative gastrectomy without any prior chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day</description>
    <arm_group_label>NAC PLUS SURGERY</arm_group_label>
    <other_name>Modified SOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Curative gastrectomy</intervention_name>
    <description>Radical gastrectomy with D2 lymph node dissection</description>
    <arm_group_label>SURGERY FIRST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histology confirmed non-obstructive adenocarcinoma of the stomach or esophagogastric&#xD;
             junction.&#xD;
&#xD;
          -  Clinical stage: cTNM: stage III&#xD;
&#xD;
          -  Performance status: Eastern Cooperative Oncology Group ECOG â‰¤ 2 (normal to symptomatic&#xD;
             but in bed less than half the day)&#xD;
&#xD;
          -  Clinically fit for systemic chemotherapy and gastric cancer surgery, i.e. adequate&#xD;
             renal, hepatic, hematologic, and pulmonary function.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically unfit for systemic chemotherapy and gastric cancer surgery, i.e.&#xD;
             uncontrolled cardiac disease, or other clinically significant uncontrolled&#xD;
             comorbidities, unable to undergo general anesthesia&#xD;
&#xD;
          -  Distant metastases (including retroperitoneal lymph node)&#xD;
&#xD;
          -  Locally advanced inoperable disease (Clinical assessment)&#xD;
&#xD;
          -  Relapse of gastric cancer&#xD;
&#xD;
          -  Malignant secondary disease&#xD;
&#xD;
          -  Prior chemo or radiotherapy&#xD;
&#xD;
          -  Inclusion in another clinical trial&#xD;
&#xD;
          -  Known contraindications or hypersensitivity for planned chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>76 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenggang Zhu</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birendra K Sah</last_name>
    <phone>0086-21-64370045</phone>
    <phone_ext>6701302</phone_ext>
    <email>rjsurgeon@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenggang Zhu</last_name>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>BIRENDRA KUMAR SAH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

